Every 8-K that MaxCyte, Inc. (MXCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MXCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MXCT filings page.
MaxCyte, Inc. reported financial results for the quarter ended June 30, 2026 and reiterated its full year 2026 guidance. Second-quarter revenue was $7,271 thousand, down from $8,507 thousand a year earlier, with instruments, consumables and license revenue lower, partially offset by higher assay services and other revenue.
The company recorded a net loss of $8,874 thousand for the quarter, improving from a $12,357 thousand net loss in 2025, and management highlighted a meaningful reduction in net loss in the first half of 2026. Royalty revenue grew to $764 thousand, and the company cited an enterprise-level multi-platform technology license with Genentech as an important recent development. As of June 30, 2026, MaxCyte held $15,042 thousand in cash and cash equivalents and $90,648 thousand in short-term investments.
MaxCyte, Inc. held its 2026 annual stockholder meeting on June 17, 2026, where investors voted on board composition and the company’s auditor. Stockholders elected three Class II directors: Patrick Balthrop, Cynthia Collins and Stanley Erck, each receiving more votes for than withheld.
Investors also ratified the Audit Committee’s selection of CohnReznick LLP as MaxCyte’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with over 70 million votes cast in favor and minimal opposition or abstentions.
MaxCyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company previously received a notice that its common stock had closed below $1.00 per share for 30 consecutive trading days, putting its Nasdaq Global Select Market listing at risk.
Nasdaq informed MaxCyte that for 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of its common stock was at or above $1.00. As a result, MaxCyte now complies with Nasdaq Listing Rule 5450(a)(1), and Nasdaq considers the matter closed.
MaxCyte, Inc. reported first quarter 2026 revenue of $9.7 million, made up of $6.2 million in core revenue and $3.4 million from Strategic Platform License (SPL) program milestones and royalties. Total revenue declined 7% year over year, but the net loss improved to $4.8 million, or $0.04 per share, from $10.3 million a year earlier as operating expenses were reduced.
The company reiterated its full year 2026 revenue guidance of $30–32 million, including core revenue of $25–27 million and SPL program-related revenue of $5 million. MaxCyte’s board authorized a $10 million share repurchase program over one year, while the balance sheet showed total assets of $194.5 million and stockholders’ equity of $167.9 million as of March 31, 2026.
MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer and principal accounting officer, effective March 30, 2026, succeeding Douglas Swirsky following a previously announced transition. Ahuja brings over 20 years of finance leadership experience from Agilent Technologies, including roles in investor relations, FP&A, operations and global financial operations.
Ahuja will receive an annual base salary of $450,000, with a target annual cash bonus equal to 50% of base salary. As an inducement to join, he will be granted a nonqualified stock option for 375,000 shares of common stock and a restricted stock unit award covering 187,500 shares. A severance agreement is expected, providing salary continuation, bonus, COBRA coverage and equity vesting acceleration if he is terminated without cause or resigns for good reason, with enhanced benefits in connection with a change of control.
MaxCyte reported weaker 2025 results and trimmed its outlook for 2026. Full year 2025 revenue was $33.0 million, down from $38.6 million, with total core revenue falling to $29.6 million. The company posted a 2025 net loss of $44.6 million and an EBITDA loss of $47.6 million, including restructuring and goodwill impairment charges.
Fourth quarter 2025 revenue was $7.3 million, a 16% decline year over year, while core revenue dropped 22%. Despite this, gross margin stayed high at 81% for 2025. Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025, and MaxCyte expects to end 2026 with at least $136 million. For 2026, it guides to total revenue of $30–32 million, including core revenue of $25–27 million and $5 million from Strategic Platform License (SPL) programs, reflecting continued customer headwinds.
MaxCyte, Inc. reported that Nasdaq notified the company its common stock no longer meets the Nasdaq Global Select Market’s minimum bid price requirement because the closing bid has been below $1.00 per share for 30 consecutive trading days. The stock remains listed for now and continues to trade on Nasdaq.
MaxCyte has 180 calendar days, until September 14, 2026, to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. If it fails to do so, the company may seek an additional 180-day period by transferring to the Nasdaq Capital Market, subject to meeting other listing standards. Nasdaq could ultimately move to delist the shares, and there is no assurance MaxCyte will regain or maintain compliance.
MaxCyte, Inc. reported that it has released preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. The company furnished a press release dated January 12, 2026 as Exhibit 99.1 to a current report on Form 8-K under the item covering results of operations and financial condition. The information in this section and the exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated by reference into other securities law filings.
MaxCyte, Inc. furnished a current report announcing preliminary unaudited financial results for the quarter ended September 30, 2025 and reiterated its full‑year 2025 revenue guidance. The details are provided in a press release attached as Exhibit 99.1. The company stated that the information is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.
MaxCyte, Inc. disclosed anticipated costs tied to a workforce reduction plan. The company expects approximately $1.8 million for severance and healthcare continuation for directly employed personnel, $0.6 million for employees engaged through employer-of-record arrangements (covering severance, benefits, and statutory notice wages in jurisdictions such as Germany, France, and the United Kingdom), $0.4 million in wages and benefits required under Maryland's Mini-WARN Act (60 days' notice or pay in lieu), and $0.1 million in other costs including legal, consulting, and administrative expenses. In total, the disclosed near-term charge sums to $2.9 million, presented as estimates associated with implementing the Plan.
MaxCyte, Inc. reported the departure of Ali Soleymannezhad from his role as Chief Commercial Officer. The company states his separation is governed by an Amended and Restated Severance Agreement dated July 1, 2024.
Under that agreement, Mr. Soleymannezhad will receive his base salary for nine months and contributions toward COBRA health care continuation for the nine-month severance period, provided he executes and complies with the agreement's release of claims. The filing references the Severance Agreement filed as exhibit 10.2 to the Company’s Quarterly Report for the quarter ended March 31, 2025. No salary amounts, successor information, or additional operational or financial details were disclosed.
Form 8-K overview: On 25 June 2025, MaxCyte, Inc. ("the Company") filed a Current Report to disclose that it has applied to the London Stock Exchange to cancel admission of its common stock to trading on AIM. The filing designates the action as an "Other Event" under Item 8.01.
Key dates: The last day of AIM trading will be 25 June 2025, and the AIM delisting becomes effective at 7:00 a.m. U.K. time on 26 June 2025.
Continuing listing: The Company explicitly states that the AIM delisting "has no impact on the Company’s Nasdaq listing," and the shares will remain traded on the Nasdaq Global Select Market under ticker MXCT.
Additional disclosure items: No financial statements, earnings data, or major transactions are included. One exhibit (Ex. 104) accompanies the filing, containing the Inline XBRL cover page.
Implications disclosed: The filing is focused solely on the administrative change in listing status; it does not describe strategic rationale, cost implications, or future capital-markets plans. Investors trading on Nasdaq are unaffected according to the Company. U.K.-based investors will cease to have on-exchange access via AIM once the delisting takes effect.